Get started
Keyword

ribociclib

Description: Ribociclib is an anticancer drug that inhibits cyclin-dependent kinases 4 and 6, used in targeted treatment of certain breast cancers.
Wikidata ID: wiki/Q27088552
OpenAlex ID: keywords/ribociclib
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
2016 · Gabriel N. Hortobagyi, Salomon M. Stemmer, et al. · New England Journal of Medicine · 2,024
PDF
Treating cancer with selective CDK4/6 inhibitors
2016 · Ben O'Leary, Richard S. Finn, et al. · Nature Reviews Clinical Oncology · 1,128
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
2018 · Dennis J. Slamon, Patrick Neven, et al. · Journal of Clinical Oncology · 1,116
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
2018 · Debu Tripathy, Seock-Ah Im, et al. · The Lancet Oncology · 1,018
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
2019 · Seock-Ah Im, Yen-Shen Lu, et al. · New England Journal of Medicine · 999
PDF
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
2018 · G.N. Hortobagyi, S.M. Stemmer, et al. · Annals of Oncology · 873
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
2019 · Dennis J. Slamon, Patrick Neven, et al. · New England Journal of Medicine · 864
PDF
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
2022 · Gabriel N. Hortobagyi, Salomon M. Stemmer, et al. · New England Journal of Medicine · 784
PDF
Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM
2017 · Kurt Engeland · Cell Death and Differentiation · 656
PDF
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
2020 · Lei Ding, Jiaqi Cao, et al. · International Journal of Molecular Sciences · 618
PDF
Targeting CDK4/6 in patients with cancer
2016 · Erika Hamilton, Jeffrey R. Infante · Cancer Treatment Reviews · 481
PDF
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
2020 · Laura M Spring, Seth A Wander, et al. · The Lancet · 471
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
2020 · C. Louwrens Braal, Elisabeth M. Jongbloed, et al. · Drugs · 439
PDF
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
2016 · Ping Chen, Nathan V. Lee, et al. · Molecular Cancer Therapeutics · 429
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
2019 · Luigi Formisano, Yao Lu, et al. · Nature Communications · 409
PDF
Ribociclib plus Endocrine Therapy in Early Breast Cancer
2024 · Dennis Slamon, Oleg Lipatov, et al. · New England Journal of Medicine · 407
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
2017 · R. Condorelli, L. Spring, et al. · Annals of Oncology · 395
Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment
2015 · Todd VanArsdale, Chris Boshoff, et al. · Clinical Cancer Research · 394
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
2018 · Robert Roskoski · Pharmacological Research · 393
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
2013 · JulieAnn Rader, Mike R. Russell, et al. · Clinical Cancer Research · 391
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
2018 · Kamal Pandey, Hee‐Jung An, et al. · International Journal of Cancer · 362
PDF
Cell-Cycle Therapeutics Come of Age
2017 · Matthew Ingham, Gary K. Schwartz · Journal of Clinical Oncology · 353
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
2016 · Jeffrey R. Infante, Philippe A. Cassier, et al. · Clinical Cancer Research · 317
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
2021 · Yen-Shen Lu, Seock-Ah Im, et al. · Clinical Cancer Research · 285
PDF
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
2021 · D.J. Slamon, P. Neven, et al. · Annals of Oncology · 280
Works count: 3,714
Citation count: 44,300
Year
Topic
Type